A low-cost, high-quality new drug discovery process using patient-derived induced pluripotent stem cells.
about
The Use of Stem Cells to Model Amyotrophic Lateral Sclerosis and Frontotemporal Dementia: From Basic Research to Regenerative MedicineFunctional metabolic interactions of human neuron-astrocyte 3D in vitro networksAdvances in Stem Cell Research- A Ray of Hope in Better Diagnosis and Prognosis in Neurodegenerative DiseasesTherapeutic opportunities and challenges of induced pluripotent stem cells-derived motor neurons for treatment of amyotrophic lateral sclerosis and motor neuron disease.Pluripotent Stem Cells and Other Innovative Strategies for the Treatment of Ocular Surface Diseases.Induced pluripotent stem cells: at the heart of cardiovascular precision medicine.Toxicity testing and drug screening using iPSC-derived hepatocytes, cardiomyocytes, and neural cells.Biochemical, cell biological, pathological, and therapeutic aspects of Krabbe's disease.Clinical potentials of human pluripotent stem cells.Chapter 17 Sterile Plate-Based Vitrification of Adherent Human Pluripotent Stem Cells and Their Derivatives Using the TWIST Method.New Models for Therapeutic Innovation from Japan.In Silico Prediction of Chemical Toxicity for Drug Design Using Machine Learning Methods and Structural Alerts.Human induced pluripotent stem cell-derived beating cardiac tissues on paper.
P2860
Q26766372-3F810534-709F-403B-AF03-8EBF541C1789Q26970775-C8C8824D-E78D-46FA-AE33-8178523AC64EQ28067160-46245AFE-AD9E-4800-AE31-999F5A660B59Q34557892-283C9B1F-C951-41E9-A4EF-90B798108BA0Q35896756-054E8C2A-50B3-4D78-9B28-5FD7296D8BBFQ38786687-0E6B031C-D8BF-41E5-8DFD-E7552A3C1A31Q38820849-5835DA4C-B470-4170-8B0F-E5CC1091464CQ38957246-F1EFAF3E-2DF0-4D0E-90DA-51D03E5C9E15Q39125379-179C53CC-05EE-4162-8B54-192F59C999DCQ41597167-822EE1AD-099F-48F0-ABBB-2294D49D2EB2Q42016113-279761ED-5E54-41AB-938C-5C761E46E926Q50420418-FDBD2E0A-B85A-41FA-96C8-DB7A6B9D7CF5Q51480688-EA41ECBA-8779-4AA0-8657-6CABF0F948E6
P2860
A low-cost, high-quality new drug discovery process using patient-derived induced pluripotent stem cells.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
A low-cost, high-quality new d ...... nduced pluripotent stem cells.
@en
type
label
A low-cost, high-quality new d ...... nduced pluripotent stem cells.
@en
prefLabel
A low-cost, high-quality new d ...... nduced pluripotent stem cells.
@en
P1433
P1476
A low-cost, high-quality new d ...... nduced pluripotent stem cells.
@en
P2093
Augustinus Bader
Shibashish Giri
P356
10.1016/J.DRUDIS.2014.10.011
P577
2014-11-15T00:00:00Z